Dengue Vaccine Development: Current Status, Challenges, and Future Perspective
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Vaccines against (re)emerging and Tropical Infections Diseases".
Deadline for manuscript submissions: 30 September 2024 | Viewed by 4100
Special Issue Editor
Special Issue Information
Dear Colleagues,
Dengue Hemorrhagic Fever (DHF) is an acute viral infectious disease caused by the dengue virus, an arthropod-borne virus belonging to the genus Flavivirus and family Flaviviridae. The disease remains a tropical and subtropical health concern because its prevalence is increasing in some areas of these regions. Consequently, there is a growing need for effective preventive interventions against dengue, the virus that causes this disease. This virus has four serotypes; therefore, an effective vaccine against these four serotypes is required to reduce the morbidity and mortality caused by this virus infection. In the last decade, enormous progress has been made in the fields of dengue virology and immunology in relation to the development of dengue vaccines.
We are pleased to invite you to contribute to the Special Issue “Dengue Vaccine Development: Current Status, Challenges, and Future Perspective”.
The availability of the dengue vaccine is crucial for public health. However, no widely used universal dengue vaccine effective for the four serotypes has been used extensively as of yet.
This Special Issue aims to collect high-quality submissions on the research and development of the dengue vaccine. In addition, research findings that identify critical challenges and suggest additional research opportunities related to the dengue vaccine's status, challenges, and future perspective are greatly appreciated.
In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: immunoinformatics, immunology, clinical trials, vaccine adjuvant, public health, and risk assessment.
We look forward to receiving your contributions.
Prof. Dr. Trina E. Tallei
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- dengue
- vaccine
- vaccine development
- adjuvant
- public health
- risk assessment
- clinical trial
